Toggle light / dark theme

đŸ€”

Gilead’s Covid-19 drug remdesivir will be priced at $3,120 for a typical U.S. patient with commercial insurance.


Gilead Sciences Inc. detailed its pricing plans for Covid-19 drug remdesivir, saying it will charge U.S. hospitals $3,120 for a typical patient with commercial insurance.

The drugmaker on Monday disclosed its pricing plans as it prepares to begin charging for the drug in July. The U.S. has been distributing remdesivir donated by Gilead since the drug was authorized for emergency use in May.

However, the situation has been improving as Chinese tech giants including e-commerce company Alibaba, search engine Baidu, on-demand delivery company Meituan Dianping, ride-hailing operator Didi Chuxing and smartphone maker Xiaomi now offer more affordable health care plans via mutual aid platforms, which operate as a collective claim-sharing mechanism.


China’s online mutual aid platforms are disrupting old school insurance companies by leveraging big data and internet finance technologies to offer low cost medical coverage.

Pluto is thought to possess a subsurface ocean beneath its thick ice shell. It has generally been assumed that the dwarf planet formed out of cold material and then later developed its ocean due to warming from radioactive decay. By combining numerical simulations with geological observations by NASA’s New Horizons mission, a team of researchers from the University of California Santa Cruz and the Southwest Research Institute demonstrated that Pluto was instead relatively hot when it formed, with an early subsurface ocean.

Canada is marching forward with its international partners to establish a permanent research installation near the Moon, the Lunar Gateway.

As it did for the Shuttle and Station programs before, the Canadian Space Agency, via a partnership with MacDonald, Dettwiler, and Associates, Inc., will build the next-generation robotic system: Canadarm3.

This smart robotic system will be Canada’s contribution to the US-led Lunar Gateway station for the Artemis Program, the next major international collaboration in human space exploration — which forms the cornerstone of Canadian space strategy.

Animal experiments demonstrating the anti-aging effects of exchanging young blood plasma for old have been prominent in the last two months. Several groups are saying it’s time to translate their findings into human trials. But I’ve recently learned that others have been doing this for several years. What can we learn from their results to guide the next steps in experimentation?

I had never heard of Grifols, the Spanish pharmaceutical company that is the world’s largest supplier of albumin. Since 2005, Grifols has been quietly funding world leaders in plasma exchange research in humans. Albutein ¼ is their brand-name solution of human albumin.

Last month, the first results of the Grifol’s AMBAR trial were released. (AMBAR stands for A lzheimer’s M odulation B y A lbumin R eplacement). It was a much larger-scale phase 2.5 trial, with 496 subjects recruited from sites in Spain and USA, and treated for 14 months. A single treatment consisted of removing 2.5 to 3 litres of blood (more than half the body’s inventory) and replacing it with Albutein. Patients began with 6 weekly treatments, and thereafter there were 12 monthly smaller plasma replacements (0.7 litres), again with Albutein.

Last year’s Netflix movie The Great Hack detailed the dark side of data collection, centered around the 2016 Cambridge Analytica scandal. The movie describes how “psychometric profiles” exist for you, me, and all of our friends. The data collected from our use of digital services can be packaged in a way that gives companies insight into our habits, preferences, and even our personalities. With this information, they can do anything from show us an ad for a pair of shoes we’ll probably like to try to change our minds about which candidate to vote for in an election.

With so much of our data already out there, plus the fact that most of us will likely keep using the free apps we’ve enjoyed for years, could it be too late to try to fundamentally change the way this model works?

Maybe not. Think of it this way: we have a long, increasingly automated and digitized future ahead of us, and data is only going to become more important, valuable, and powerful with time. There’s a line (which some would say we’ve already crossed) beyond which the amount of data companies have access to and the way they can manipulate it for their benefit will become eerie and even dystopian.